Heart failure & cardiomyopathies
Interleukin-1 Blockade in Heart Failure: An On-Treatment and Off-Treatment Cardiorespiratory Fitness Analysis
Authors' conclusion
These data validate IL-1 as an active and dynamic modulator of cardiac function and cardiorespiratory fitness in HF.
Study context
- Population
- Patients with HF; 37 (51%) females, 52 (71%) Black-African-American46 with off-treatment data
- Participants
- 73 patients
- Comparison
- On-treatment with anakinra vs baseline, and off-treatment after cessation
- Off-treatmentn = 46
- Outcome
- Changes in cardiorespiratory fitness and cardiac function on-treatment with anakinra and off-treatment
Methodological detailson-treatment and off-treatment, before-after
- On-treatment and off-treatment
- Before-after
Pooled result
As reported in the abstract
VO2peak (on-treatment) · 4 [2-12] weeks
P < 0.001
Further pooled results
| Outcome | On-treatment | Off-treatment | P value |
|---|---|---|---|
| hs-CRP (on-treatment) · 4 [2-12] weeksOn-treatment vs Baseline | median 1.4 (IQR 0.8–3.4) mg/L | — not stated in the abstract | P < 0.001 |
| VO2peak (off-treatment, n=46) · 12 [4-12] weeks after cessationOff-treatment vs On-treatment · off-treatment analysis · median, mL/kg/min | 16.2 (IQR 14.0–18.4) | 14.9 (IQR 11.5–17.8) | P = 0.017 |
| CRP (off-treatment, n=46) · 12 [4-12] weeks after cessationOff-treatment vs On-treatment · off-treatment analysis · median | 1.5 (IQR 1.0–3.4) | 5.9 (IQR 1.8–13.1) | P = 0.001 |
— not stated in the abstract
- hs-CRP (on-treatment): Baseline median 6.2 (IQR 3.3–15.4) mg/L
Original publication
Interleukin-1 Blockade in Heart Failure: An On-Treatment and Off-Treatment Cardiorespiratory Fitness Analysis. ESC Heart Fail. Published 4 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →